MOUNJARO 2.5MG KWIKPEN

How MOUNJARO 2.5MG KWIKPEN Works

• Tirzepatide is a single molecule that activates two natural incretin hormone receptors — GIP and GLP-1. Through these, it lowers blood sugar in several complementary ways: it prompts the pancreas to release more insulin when blood sugar is high, reduces the release of glucagon (which raises blood sugar), improves the body's sensitivity to insulin, and slows the emptying of the stomach. Acting on appetite centres in the brain, it also increases fullness and reduces hunger, which is why it commonly leads to weight loss. Because insulin release is glucose-dependent, the risk of low blood sugar on its own is low.

Most side effects are digestive and are most common when starting or increasing the dose; they usually ease over time. Common: nausea, diarrhoea, reduced appetite, vomiting, constipation, indigestion, and abdominal pain. Injection-site reactions and tiredness can also occur. Others: mild dizziness; if combined with insulin or a sulfonylurea, low blood sugar (hypoglycaemia). Prolonged vomiting/diarrhoea can cause dehydration and affect the kidneys. Serious (seek medical attention): signs of pancreatitis (severe, persistent stomach pain that may spread to the back, with or without vomiting); gallbladder problems (upper-right abdominal pain, fever, yellowing of skin/eyes); severe allergic reactions; and vision changes in people with diabetic eye disease. Tirzepatide carries a boxed warning about a risk of thyroid C-cell tumours seen in animals; it should not be used by people with a personal or family history of medullary thyroid cancer or MEN 2.

• Keep MOUNJARO 2.5MG KWIKPEN 0.6ML away from the reach of children and pets.
• Store MOUNJARO 2.5MG KWIKPEN 0.6ML in a refrigerator (2 - 8°C). Do not freeze.